Biologics weigh on group plans
By
Alain Thériault
|
Oct. 20, 2022, 10:48 a.m.
Flash |
HBM+ |
TELUS |
AFL |
AGA FINANCIAL GROUP |
GREEN SHIELD CANADA |
SYNEX |
PEOPLE CORPORATION |
Medication |
Indemnisation |
COVID19 |
Magazine supplement

Photo: Freepik | senivpetro
Biologics are putting a strain on private group plans by treating orphan diseases, as well as common diseases, at high cost.
This article is reserved to PRO Level subscribers
Discover the PRO Level
Already subscribed? Sign in >
You are already subscribed
If your access is suspended, please verify and update your credit card in your profile.
Advertisement
The most popular in Health
Headlines
Advertisement
Related topics …